CD79A and cancer: The study’s focus on anti-EBV antibody responses could explore how sex differences in IgA levels or activity contribute to the immune system’s ability to control or eliminate EBV, a well-known virus directly involved in the immunopathogenesis of several cancers, including those of the head and neck.